Dipeptidyl peptidase 4 (DPP-4) inhibitors in patients with cirrhosis and diabetes

Background and Aim: DPP4 inhibitors have pleiotropic effects. Studies are limited on safety profile of DPP-4 in patients with cirrhosis diabetes. Aim is to study effect liver function tests diabetes cirrhosis. Methods: All consecutive who were started within one month included. Patients’ functions HbA1c monitored every three months for 6 months. Patients followed up monthly any possible side effects related DPP 4 inhibitors. Results: 57 (M:F: 37:20) enrolled mean age 59± 9 yrs, weight 72±12 kg, etiology NASH, n= 54(96%)[CTP A:B:C:41:16:0] duration 9±4 yrs. Mean Fibroscan was 36±16Kpa 19(33%) had esophageal varices suggesting significant clinical portal hypertension.39(68%) sitagliptin,13(23%) vildagliptin, linagliptin n=4(175) one(2%) taking teneligliptin. 40 (70%) metformin 4(7%) also SGLT-2 Nausea bloating seen 6(2%), non specific muscle pain 3(1%), upper respiratory infection acute pancreatitis, n=1. Conclusion: safe patient compensated did not affect over a follow